Privia Health Group (NASDAQ:PRVA – Get Free Report) had its target price lifted by Canaccord Genuity Group from $32.00 to $33.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target suggests a potential upside of 36.16% from the company’s current price.
Other research analysts have also issued research reports about the stock. Piper Sandler raised their price objective on shares of Privia Health Group from $36.00 to $38.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a research note on Tuesday, September 29th. Citigroup reissued a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Finally, Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Privia Health Group currently has an average rating of “Moderate Buy” and a consensus target price of $31.23.
Read Our Latest Report on Privia Health Group
Privia Health Group Price Performance
PRVA stock traded up $0.30 during midday trading on Friday, reaching $24.24. 1,421,188 shares of the stock were exchanged, compared to its average volume of 1,064,856. Privia Health Group has a 52 week low of $18.92 and a 52 week high of $28.82. The company has a fifty day moving average price of $20.97 and a 200 day moving average price of $22.63. The stock has a market capitalization of $3.10 billion, a PE ratio of 115.56 and a beta of 0.76.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.09 by $0.12. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%. The firm had revenue of $656.96 million during the quarter, compared to the consensus estimate of $610.72 million. During the same period last year, the company earned $0.29 earnings per share. The business’s quarterly revenue was up 13.2% on a year-over-year basis. As a group, analysts anticipate that Privia Health Group will post 0.27 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Privia Health Group
A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in Privia Health Group during the second quarter worth $550,684,000. Rubicon Founders LLC bought a new stake in Privia Health Group during the second quarter valued at $153,635,863. Van Berkom & Associates Inc. boosted its position in Privia Health Group by 5.4% during the first quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock valued at $83,371,000 after acquiring an additional 208,787 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Privia Health Group during the second quarter valued at $74,425,000. Finally, Dimensional Fund Advisors LP grew its holdings in Privia Health Group by 6.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,406,717 shares of the company’s stock worth $49,500,000 after acquiring an additional 142,679 shares during the period. 94.48% of the stock is owned by institutional investors.
More Privia Health Group News
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: Privia reported Q3 revenue of $656.96 million, above the $610.72 million consensus and up 13.2% year over year. Reported EPS of $0.21 also beat the $0.09 consensus. The company raised full-year guidance across key financial metrics; year-to-date adjusted EBITDA rose 21.9%. These results and the improved outlook support investor optimism. Privia Health Q3 results and guidance
- Positive Sentiment: Piper Sandler raised its price target to $38 from $36 and maintained an “overweight” rating, signaling confidence in the shares’ upside potential. Piper Sandler recommendations
- Positive Sentiment: A valuation analysis published after the earnings report said PRVA could be undervalued, adding to the favorable post-earnings narrative. Valuation analysis
- Negative Sentiment: Despite the beat, the reported $0.21 EPS was below the $0.29 recorded in the year-ago quarter, and the company’s net margin remains modest at 1.19%—potential points of caution for investors. Quarterly earnings details
About Privia Health Group
Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.
Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.
See Also
- Five stocks we like better than Privia Health Group
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
